Apogee’s Zumilokibart Achieves 85% Week 16 Maintenance at Six-Month Dosing, Secures $403M
APGE•Apogee reported 52-week APEX Phase 2 Part A results for zumilokibart in atopic dermatitis, with 85% of Week 16 EASI-75 responders maintaining response at six-month dosing. The company raised $403 million, boosting cash to $1.3 billion, extending runway to 2029 for AD BLA filing, with APEX Phase 2 Part B readout due in Q2.
1. APEX Phase 2 Part A 52-Week Results
Apogee’s APEX Phase 2 Part A trial evaluated 360 mg of zumilokibart at three- and six-month intervals in moderate-to-severe atopic dermatitis. Of patients achieving EASI-75 at Week 16, 75% at three-month dosing and 85% at six-month dosing maintained response at Week 52, with safety and tolerability consistent with class profiles.
2. Upsized $403 Million Equity Offering
Following the Part A readout, Apogee completed an upsized public equity offering that generated $403 million in gross proceeds. This boost raised total cash to $1.3 billion, funding operations through 2029 and supporting a planned biologics license application filing for AD.
3. Upcoming Milestones and Pipeline Expansion
APEX Phase 2 Part B data are expected in Q2 to inform induction dosing for the planned Phase 3 atopic dermatitis program, with Phase 3 trials slated to start later this year. The company also plans to detail expansion into asthma and eosinophilic esophagitis studies and advance combination candidates APG279 and APG273 in head-to-head and respiratory trials.
